CoChat
Sign Up
Cited by 293

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Targeting senescent cells in translational medicine

Paez‐Ribes, Marta, González‐Gualda, Estela, Doherty, Gary J, Muñoz‐Espín, Daniel·2019·EMBO Molecular Medicine
DOI 10.15252/emmm.201810234PMC PMC6895604
Open this paper in CoChat — free account

Abstract

Organismal ageing is a complex process driving progressive impairment of functionality and regenerative potential of tissues. Cellular senescence is a state of stable cell cycle arrest occurring in response to damage and stress and is considered a hallmark of ageing. Senescent cells accumulate in multiple organs during ageing, contribute to tissue dysfunction and give rise to pathological manifestations. Senescence is therefore a defining feature of a variety of human age‐related disorders, including cancer, and targeted elimination of these cells has recently emerged as a promising therapeutic approach to ameliorate tissue damage and promote repair and regeneration. In addition, in vivo identification of senescent cells has significant potential for early diagnosis of multiple pathologies. Here, we review existing senolytics, small molecules and drug delivery tools used in preclinical therapeutic strategies involving cellular senescence, as well as probes to trace senescent cells. We also review the clinical research landscape in senescence and discuss how identifying and targeting cellular senescence might positively affect pathological and ageing processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201810234

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most known senolytics target pathways that are mutated in cancer, which limits their applicability as therapeutic agents.

    “most known senolytics target pathways that are mutated in cancer, which limits their applicability as therapeutic agents32”

    From Discovery of senolytics using machine learning (2023) · cites this paper as [32]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 70

  1. Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D et al (2013) Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 502: 340–345 · DOI · Paper page
  2. Agostini A, Mondragõn L, Bernardos A, Martínez‐Máñez R, Dolores Marcos M, Sancenõn F, Soto J, Costero A, Manguan‐García C, Perona R et al (2012) Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew Chem Int Ed 51: 10556–10560 · DOI
  3. Alimbetov D, Davis T, Brook AJC, Cox LS, Faragher RGA, Nurgozhin T, Zhumadilov Z, Kipling D (2016) Suppression of the senescence‐associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology 17: 305–315 · DOI · Paper page
  4. Althubiti M, Lezina L, Carrera S, Jukes‐Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K et al (2014) Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis 5: e1528 · DOI · Paper page
  5. Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E, Salifoglou A (2015) Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci 16: 1691–1710 · DOI
  6. Asanuma D, Sakabe M, Kamiya M, Yamamoto K, Hiratake J, Ogawa M, Kosaka N, Choyke PL, Nagano T, Kobayashi H et al (2015) Sensitive β‐galactosidase‐targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo. Nat Commun 6: 6463 · DOI
  7. Biran A, Zada L, Abou Karam P, Vadai E, Roitman L, Ovadya Y, Porat Z, Krizhanovsky V (2017) Quantitative identification of senescent cells in aging and disease. Aging Cell 16: 661–671 · DOI · Paper page
  8. Burton DGA, Stolzing A (2018) Cellular senescence: immunosurveillance and future immunotherapy. Ageing Res Rev 43: 17–25 · DOI · Paper page
  9. Cang S, Iragavarapu C, Savooji J, Song Y, Liu D (2015) ABT‐199 (venetoclax) and BCL‐2 inhibitors in clinical development. J Hematol Oncol 8: 129 · DOI
  10. Chang J, Wang Y, Shao L, Laberge R‐M, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W et al (2016) Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22: 78–83 · DOI · Paper page
  11. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM (2014) Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep 15: 1139–1153 · DOI · Paper page
  12. Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, Van Deursen JM (2016) Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354: 472–477 · DOI · Paper page
  13. Debacq‐Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O (2009) Protocols to detect senescence‐associated beta‐galactosidase (SA‐betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4: 1798–1806 · DOI · Paper page
  14. Demaria M, O'Leary MN, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM et al (2017) Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov 7: 165–176 · DOI · Paper page
  15. Dey A, Tergaonkar V, Lane DP (2008) Double‐edged swords as cancer therapeutics: simultaneously targeting p53 and NF‐kappaB pathways. Nat Rev Drug Discov 7: 1031–1040 · DOI
  16. Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J, Helin K, Hansen KH (2007) Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A‐ARF locus. EMBO J 26: 1637–1648 · DOI · Paper page
  17. Ekpenyong‐Akiba AE, Canfarotta F, Abd HB, Poblocka M, Casulleras M, Castilla‐Vallmanya L, Kocsis‐Fodor G, Kelly ME, Janus J, Althubiti M et al (2019) Detecting and targeting senescent cells using molecularly imprinted nanoparticles. Nanoscale Horizons 4: 757–768 · DOI
  18. Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy‐induced senescence in cancer. J Natl Cancer Inst 102: 1536–1546 · DOI · Paper page
  19. Frescas D, Roux CM, Aygun‐Sunar S, Gleiberman AS, Krasnov P, Kurnasov OV, Strom E, Virtuoso LP, Wrobel M, Osterman AL et al (2017) Senescent cells expose and secrete an oxidized form of membrane‐bound vimentin as revealed by a natural polyreactive antibody. Proc Natl Acad Sci USA 114: E1668–E1677 · DOI · Paper page
  20. Fuhrmann‐Stroissnigg H, Ling YY, Zhao J, McGowan SJ, Zhu Y, Brooks RW, Grassi D, Gregg SQ, Stripay JL, Dorronsoro A et al (2017) Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 8: 422 · DOI · Paper page
  21. Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R et al (2018) Targeting STING with covalent small‐molecule inhibitors. Nature 559: 269–273 · DOI · Paper page
  22. Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT et al (2015) Small‐molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell 27: 852–863 · DOI
  23. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, Meldrum E, Sanders YY, Thannickal VJ (2014) Reversal of persistent fibrosis in aging by targeting Nox4‐Nrf2 redox imbalance. Sci Transl Med 6: 231ra47 · DOI · Paper page
  24. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin‐6 and its receptor in cancer: implications for translational therapeutics. Cancer 110: 1911–1928 · DOI · Paper page
  25. Hou J, Cui C, Kim S, Sung C, Choi C (2018) Ginsenoside F1 suppresses astrocytic senescence‐associated secretory phenotype. Chem Biol Interact 283: 75–83 · DOI
  26. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y (1994) Expression of bcl‐2 in small cell lung carcinoma cells. Cancer Res 54: 6–8
  27. Imrali A, Mao X, Yeste‐Velasco M, Shamash J, Lu Y (2016) Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res 6: 1772–1784
  28. Ke S, Lai Y, Zhou T, Li L, Wang Y, Ren L, Ye S (2018) Molybdenum disulfide nanoparticles resist oxidative stress‐mediated impairment of autophagic flux and mitigate endothelial cell senescence and angiogenic dysfunctions. ACS Biomater Sci Eng 4: 663–674 · DOI
  29. Kim H‐N, Chang J, Shao L, Han L, Iyer S, Manolagas SC, O'Brien CA, Jilka RL, Zhou D, Almeida M (2017a) DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell 16: 693–703 · DOI · Paper page
  30. Laberge R‐M, Zhou L, Sarantos MR, Rodier F, Freund A, de Keizer PLJ, Liu S, Demaria M, Cong Y‐S, Kapahi P et al (2012) Glucocorticoids suppress selected components of the senescence‐associated secretory phenotype. Aging Cell 11: 569–578 · DOI · Paper page
  31. Lamming DW, Ye L, Sabatini DM, Baur JA (2013) Rapalogs and mTOR inhibitors as anti‐aging therapeutics. J Clin Invest 123: 980–989 · DOI · Paper page
  32. Lee HW, Heo CH, Sen D, Byun HO, Kwak IH, Yoon G, Kim HM (2014) Ratiometric two‐photon fluorescent probe for quantitative detection of β‐galactosidase activity in senescent cells. Anal Chem 86: 10001–10005 · DOI
  33. Lee S, Schmitt CA (2019) The dynamic nature of senescence in cancer. Nat Cell Biol 21: 94–101 · DOI · Paper page
  34. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM (2008) Senescence‐associated exosome release from human prostate cancer cells. Cancer Res 68: 7864–7871 · DOI · Paper page
  35. Leontieva OV, Demidenko ZN, Blagosklonny MV (2015) Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget 6: 23238–23248 · DOI
  36. Li T, Chen ZJ (2018) The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med 215: 1287–1299 · DOI · Paper page
  37. Liu Z, Wild C, Ding Y, Ye N, Chen H, Wold EA, Zhou J (2016) BH4 domain of Bcl‐2 as a novel target for cancer therapy. Drug Discov Today 21: 989–996 · DOI
  38. Lozano‐Torres B, Galiana I, Rovira M, Garrido E, Chaib S, Bernardos A, Muñoz‐Espín D, Serrano M, Martínez‐Máñez R, Sancenón F (2017) An OFF‐ON two‐photon fluorescent probe for tracking cell senescence in vivo. J Am Chem Soc 139: 8808–8811 · DOI
  39. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M et al (2014) Dominant‐activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15: 88–97 · DOI
  40. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S (2011) Protein‐nanoparticle interactions: opportunities and challenges. Chem Rev 111: 5610–5637 · DOI
  41. Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA et al (2018) Senescence‐associated reprogramming promotes cancer stemness. Nature 553: 96–100 · DOI · Paper page
  42. Moiseeva O, Deschênes‐Simard X, St‐Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G (2013) Metformin inhibits the senescence‐associated secretory phenotype by interfering with IKK/NF‐κB activation. Aging Cell 12: 489–498 · DOI · Paper page
  43. Ovadya Y, Krizhanovsky V (2018) Strategies targeting cellular senescence. J Clin Invest 128: 1247–1254 · DOI · Paper page
  44. Pellegrini G, Dellambra E, Paterna P, Golisano O, Traverso CE, Rama P, Lacal P, De Luca M (2004) Telomerase activity is sufficient to bypass replicative senescence in human limbal and conjunctival but not corneal keratinocytes. Eur J Cell Biol 83: 691–700 · DOI
  45. Pitozzi V, Mocali A, Laurenzana A, Giannoni E, Cifola I, Battaglia C, Chiarugi P, Dolara P, Giovannelli L (2013) Chronic resveratrol treatment ameliorates cell adhesion and mitigates the inflammatory phenotype in senescent human fibroblasts. J Gerontol Ser A 68: 371–381 · DOI
  46. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D‐dependent and tumor necrosis factor‐related apoptosis‐inducing ligand‐dependent manners. Gastroenterology 130: 435–452 · DOI · Paper page
  47. van Rhee F, Wong RS, Munshi N, Rossi J‐F, Ke X‐Y, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK et al (2014) Siltuximab for multicentric Castleman's disease: a randomised, double‐blind, placebo‐controlled trial. Lancet Oncol 15: 966–974 · DOI · Paper page
  48. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, Ridker P, Lorenzatti A, Krum H, Varigos J et al (2017) Effect of interleukin‐1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double‐blind, placebo‐controlled trial. Lancet 390: 1833–1842 · DOI · Paper page
  49. Ritschka B, Storer M, Mas A, Heinzmann F, Ortells MC, Morton JP, Sansom OJ, Zender L, Keyes WM (2017) The senescence‐associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev 31: 172–183 · DOI · Paper page
  50. Roos CM, Zhang B, Palmer AK, Ogrodnik MB, Pirtskhalava T, Thalji NM, Hagler M, Jurk D, Smith LA, Casaclang‐Verzosa G et al (2016) Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15: 973–977 · DOI · Paper page
  51. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS et al (2012) Phase II study of single‐agent navitoclax (ABT‐263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18: 3163–3169 · DOI
  52. Sharpless NE, Sherr CJ (2015) Forging a signature of in vivo senescence. Nat Rev Cancer 15: 397–408 · DOI · Paper page
  53. Sinnett‐Smith J, Kisfalvi K, Kui R, Rozengurt E (2013) Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 430: 352–357 · DOI
  54. Soto‐Gamez A, Demaria M (2017) Therapeutic interventions for aging: the case of cellular senescence. Drug Discov Today 22: 786–795 · DOI · Paper page
  55. Soto‐Gamez A, Quax WJ, Demaria M (2019) Regulation of survival networks in senescent cells: from mechanisms to interventions. J Mol Biol 431: 2629–2643 · DOI · Paper page
  56. Storer M, Mas A, Robert‐Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, Yosef R, Pilpel N, Krizhanovsky V, Sharpe J et al (2013) Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155: 1119–1130 · DOI · Paper page
  57. Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD, Rosen LS (2015) Safety, efficacy, and pharmacokinetics of navitoclax (ABT‐263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 76: 1025–1032 · DOI
  58. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537–549 · DOI
  59. Urbanelli L, Buratta S, Sagini K, Tancini B, Emiliani C (2016) Extracellular vesicles as new players in cellular senescence. Int J Mol Sci 17: e1408 · DOI
  60. Vergel M, Carnero A (2010) Bypassing cellular senescence by genetic screening tools. Clin Transl Oncol 12: 410–417 · DOI
  61. Vlahovic G, Karantza V, Wang D, Cosgrove D, Rudersdorf N, Yang J, Xiong H, Busman T, Mabry M (2014) A phase I safety and pharmacokinetic study of ABT‐263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest New Drugs 32: 976–984 · DOI
  62. Wang F, Marshall CB, Yamamoto K, Li G‐Y, Plevin MJ, You H, Mak TW, Ikura M (2008) Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. J Mol Biol 384: 590–603 · DOI
  63. Wang R, Yu Z, Sunchu B, Shoaf J, Dang I, Zhao S, Caples K, Bradley L, Beaver LM, Ho E et al (2017) Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2‐independent mechanism. Aging Cell 16: 564–574 · DOI · Paper page
  64. Wang Y, Liu J, Ma X, Cui C, Deenik PR, Henderson PKP, Sigler AL, Cui L (2019) Real‐time imaging of senescence in tumors with DNA damage. Sci Rep 9: 2102 · DOI
  65. Wehrman TS, von Degenfeld G, Krutzik PO, Nolan GP, Blau HM (2006) Luminescent imaging of beta‐galactosidase activity in living subjects using sequential reporter‐enzyme luminescence. Nat Methods 3: 295–301 · DOI
  66. Xu D, Tahara H (2013) The role of exosomes and microRNAs in senescence and aging. Adv Drug Deliv Rev 65: 368–375 · DOI
  67. Yang H, Wang H, Ren J, Chen Q, Chen ZJ (2017) cGAS is essential for cellular senescence. Proc Natl Acad Sci USA 114: E4612–E4620
  68. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann‐Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL et al (2018) Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36: 18–28 · DOI · Paper page
  69. Zhang J, Li C, Dutta C, Fang M, Zhang S, Tiwari A, Werner T, Luo F‐T, Liu H (2017) A novel near‐infrared fluorescent probe for sensitive detection of β‐galactosidase in living cells. Anal Chim Acta 968: 97–104 · DOI · Paper page
  70. Zhu Y, Tchkonia T, Fuhrmann‐Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB et al (2016) Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors. Aging Cell 15: 428–435 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D.
ORCID
Muñoz‐Espín, Daniel
Venue
EMBO Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2019-11-19
Volume
11
Issue
12
ISSN
  • 1757-4676
  • 1757-4684
DOI
10.15252/emmm.201810234
PMC
PMC6895604
Cited by
293
References
64
Language
en
Licence
Funders
  • La Caixa” Foundation
  • UK Research and Innovation|Medical Research Council (MR/R000530/1)
  • Cancer Research UK (C62187/A26989)
  • Royal Society (RG160806)
  • University of Cambridge (C9685/125117)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review